THERAPY DOSSIER · th-5297ce6b2bc6

Angiopoietin-1-expressing human adipose-derived stem cells genetically modified with a baculovirus TAT peptide/DNA nanocomplex (hASC-Ang1)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22334788 ↗2012Reported benefit

Angiopoietin-1-expressing adipose stem cells genetically modified with baculovirus nanocomplex: investigation in rat heart with acute infarction.

MixedOtherImmunocompetent Lewis rats (Charles River)Female (rats); human cells from a male donorn = n = 8 per group for echocardiography and infarct size (24 r…Intramyocardial, three peri-infarct left ventricular injections using a 27 gauge needleApproximately 3 million hASCs in 300 microlitre culture med…15 minutes after coronary artery ligation

Model: Acute myocardial infarction by left thoracotomy through the fourth intercostal space and ligation of the left coronary artery 2 mm from its origin with 7-0 polypropylene suture, under 3% isoflurane

hASC-Ang1 gave higher cell retention, greater capillary density and reduced infarct size, with ejection fraction 46.28 plus or minus 6.3 per cent versus 36.35 plus or minus 5.7 per cent for unmodified hASC at 28 days after infarction.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…